RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Molecular Partners - Stock

Molecular Partners EBIT 2024

Molecular Partners EBIT

-64.94 M CHF

Ticker

MOLN.SW

ISIN

CH0256379097

WKN

A12DEH

In 2024, Molecular Partners's EBIT was -64.94 M CHF, a 6.27% increase from the -61.11 M CHF EBIT recorded in the previous year.

The Molecular Partners EBIT history

YEAREBIT (undefined CHF)
2030e187.05
2029e135.97
2028e-49.96
2027e-68.69
2026e-82.31
2025e-70.04
2024e-64.94
2023-61.11
2022116.61
2021-63.42
2020-58.33
2019-36.66
2018-37.41
2017-25.84
2016-19.49
2015-2.22
20141.84
20137.12

Molecular Partners Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Molecular Partners, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Molecular Partners from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Molecular Partners’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Molecular Partners. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Molecular Partners’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Molecular Partners’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Molecular Partners’s growth potential.

Molecular Partners Revenue, Profit, and EBIT History

DateMolecular Partners RevenueMolecular Partners EBITMolecular Partners Net Income
2030e361.52 M undefined187.05 M undefined118.41 M undefined
2029e218.08 M undefined135.97 M undefined13.16 M undefined
2028e82.57 M undefined-49.96 M undefined-39.47 M undefined
2027e45.8 M undefined-68.69 M undefined-57.56 M undefined
2026e15.64 M undefined-82.31 M undefined-74.46 M undefined
2025e15.98 M undefined-70.04 M undefined-62.78 M undefined
2024e12.92 M undefined-64.94 M undefined-57.37 M undefined
20237.04 M undefined-61.11 M undefined-61.98 M undefined
2022189.6 M undefined116.61 M undefined117.85 M undefined
20219.75 M undefined-63.42 M undefined-63.79 M undefined
20209.34 M undefined-58.33 M undefined-62.76 M undefined
201920.38 M undefined-36.66 M undefined-36.29 M undefined
201810.36 M undefined-37.41 M undefined-37.04 M undefined
201720.02 M undefined-25.84 M undefined-25.43 M undefined
201623.04 M undefined-19.49 M undefined-18.61 M undefined
201529.12 M undefined-2.22 M undefined-149,000 undefined
201426.63 M undefined1.84 M undefined-2.28 M undefined
201332.42 M undefined7.12 M undefined7.14 M undefined

Molecular Partners stock margins

The Molecular Partners margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Molecular Partners. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Molecular Partners.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Molecular Partners's sales revenue. A higher gross margin percentage indicates that the Molecular Partners retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Molecular Partners's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Molecular Partners's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Molecular Partners's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Molecular Partners. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Molecular Partners's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Molecular Partners Margin History

Molecular Partners Gross marginMolecular Partners Profit marginMolecular Partners EBIT marginMolecular Partners Profit margin
2030e99.86 %51.74 %32.75 %
2029e99.86 %62.35 %6.03 %
2028e99.86 %-60.5 %-47.8 %
2027e99.86 %-150 %-125.69 %
2026e99.86 %-526.3 %-476.09 %
2025e99.86 %-438.3 %-392.89 %
2024e99.86 %-502.63 %-444.03 %
202399.86 %-868.26 %-880.7 %
202299.47 %61.5 %62.16 %
202199.38 %-650.17 %-653.94 %
202093.99 %-624.21 %-671.7 %
201999.75 %-179.86 %-178.03 %
201879.7 %-361.27 %-357.66 %
201799.7 %-129.12 %-127.05 %
201699.74 %-84.57 %-80.78 %
201596 %-7.62 %-0.51 %
201499.32 %6.91 %-8.56 %
201396.24 %21.96 %22.02 %

Molecular Partners Aktienanalyse

What does Molecular Partners do?

Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Molecular Partners's EBIT

Molecular Partners's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Molecular Partners's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Molecular Partners's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Molecular Partners’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Molecular Partners Stock

How much did Molecular Partners achieve in EBIT for the current year?

In the current year, Molecular Partners has achieved an EBIT of -64.94 M CHF.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Molecular Partners.

How has the EBIT of Molecular Partners developed in recent years?

The EBIT of Molecular Partners has increased by 6.271% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Molecular Partners?

The EBIT of Molecular Partners is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Molecular Partners pay?

Over the past 12 months, Molecular Partners paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Partners is expected to pay a dividend of 0 CHF.

What is the dividend yield of Molecular Partners?

The current dividend yield of Molecular Partners is .

When does Molecular Partners pay dividends?

Molecular Partners pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Partners?

Molecular Partners paid dividends every year for the past 0 years.

What is the dividend of Molecular Partners?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Partners located?

Molecular Partners is assigned to the 'Health' sector.

Wann musste ich die Aktien von Molecular Partners kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Partners from 6/28/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Molecular Partners pay the last dividend?

The last dividend was paid out on 6/28/2024.

What was the dividend of Molecular Partners in the year 2023?

In the year 2023, Molecular Partners distributed 0 CHF as dividends.

In which currency does Molecular Partners pay out the dividend?

The dividends of Molecular Partners are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Molecular Partners

Our stock analysis for Molecular Partners Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Partners Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.